BioIVT will help to generate drug discovery target validation data and characterize novel therapeutics
Royston, UK – Sept. 24, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has joined UK Medicines Discovery Catapult’s Discovery Services Platform, partnering with other best-in-class service providers to help improve preclinical drug discovery success rates.
From its GLP-accredited UK facility, BioIVT’s PHASEZERO® Research Services team will provide specialist support for generating human tissue-based…
Harpenden, UK, 24 September 2019: St George Street Capital (SGSC), a UK registered charity, has signed a license agreement with AstraZeneca to develop two compounds in the clinic: one for idiopathic male infertility, and the other for renal transplant rejection. The agreement enables additional compounds to be added in the future.
The two compounds to be developed are part of AstraZeneca’s Emerging Innovation Unit, which explores drug re-purposing for novel indications by working with academic institutions through its Open Innovation programme (www.openinnovation.astrazeneca.com). The…
Aston Particle Technologies (APT) has significantly expanded its in-house R&D capabilities by investing in two benchtop systems – designed by Ely-based GB Innomech (Innomech) – to prepare small quantities of blended pharmaceutical powders for use in its formulation development projects for pharmaceutical companies.
APT is already working with a number of large multinational pharmaceutical companies but the two new systems will allow it to further increase its commercialisation activities and the number and scale of development projects it can work on simultaneously. The new systems could…
Global Regulatory Services (GRS) spins out new Irish Consultancy, Med-Di-Dia, to focus on EU MedTech
GRS spins out new Irish Consultancy, Med-Di-Dia (www.med-di-dia.com), to focus on EU MedTech regulations and quality compliance requirements. The official launch was held in Galway on Monday 16th September 2019. We were delighted to welcome the Mayor of Galway, Councillor Mike Cubbard, who started our celebrations with a thoughtful and supportive speech. And talking about ‘support’, we’ve had such a warm welcome by the Galway Technology Centre (where the new office is), Galway City and Ireland as a whole. Everyone has been so helpful. It just goes to show how collaboration really works…
Cambridge 23September 2019:As the second cohort of Accelerate@Babraham start up competition winners begin their five-month programme, the Babraham Research Campus has confirmed a further injection of financial and mentoring support for the initiative from new sponsors LifeArc. The additional funding will bolster the ability of the Babraham Research Campus to drive innovation in early science within the Cambridge life science cluster.
This year’s Accelerate@Babraham competition awarded five ventures a cash prize of £10,000 each and access to laboratory and office facilities at the…
AMSBIO has launched a range of ELISA Host Cell Protein (HCP) detection kits that allow you to detect the presence of host cell protein impurities in your therapeutic at any phase of your product development.Host cells used as expression systems in biopharmaceutical products contain hundreds to thousands of HCPs. It is crucial to sufficiently remove HCPs from your biologic early, as high concentrations can affect the safety and efficacy of your drug. The FDA has regulated that HCPs should be reduced to low levels.The new HCP detection kits from AMSBIO are based on a sandwich ELISA…
PredictImmune Announces New ‘Framework Agreement’ with Cambridge Enterprise to Allow Future Expansion of Original IP License to Expand its Commercial Product Pipeline; Extending the Benefits of Prognostic Testing to Include Systemic Lupus Erythematosus (SLE)
The agreement will enable PredictImmune to broaden its product range through the development and commercialisation of a prognostic test for SLE
Cambridge, UK, 19 September 2019: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-…
17 September 2019
Cambridge Innovation Capital (CIC), the venture capital investor enabling visionaries to build global, category-leading companies in the Cambridge ecosystem, has participated in the £195 million ($240 million) Series C funding round raised by CMR Surgical, the Cambridge-based company developing, manufacturing and marketing the next-generation surgical robotic system, Versius®. CIC was an early investor in CMR Surgical having first invested in the company’s Series A round in 2016. It has continued to provide financial support and guidance, enabling the realisation of the…
A £5m grant has been awarded by Health Data Research UK (HDR UK) to establish a health data research hub for inflammatory bowel disease (IBD) after a successful bid led by Eastern AHSN and Cambridge University Hospital Partners.
The Cambridge-based hub, to be known as G.I. Know, will be one of seven hubs set up across the UK to speed up research for new medicines and treatments, support quicker diagnoses and potentially save lives.
G.I. Know will work with patients, industry, academia and the health service to transform our understanding of inflammatory bowel disease, drive improvements in…
Cambridge, UK/MA, September 11 2019: Cedilla Therapeutics and o2h Discovery are pleased to announce multi FTE expansion to their synthetic chemistry collaboration with Cedilla Therapeutics, a Third Rock backed biotech company based in the Cambridge MA.
Cedilla Therapeutics is discovering and exploiting unique insights into protein stability. Cedilla’s integrated, multi-faceted approach has the potential to broaden the reach of small molecules by generating therapeutics that degrade protein targets as their primary mechanism of action.
o2h is pleased to collaborate with Cedilla, to support…